A Phase 1 Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma

Contact:

212-342-5162

NCT Number:

NCT05685602

Protocol:

AAAU6715

Study Status:

Active/Enrolling

Population:

Adult

Phase:

I

The purpose of this study is to test the safety of a drug called CA-4948 in combination with gemcitabine and nab-paclitaxel. This study tests different doses of the drug CA-4948 to see which dose is safer for people. There will be about 36 people taking part in this study. CA- 4948 is not approved by the FDA for treatment of pancreatic cancer.

Are you Eligible? (Inclusion Criteria)

  • Are you 18 years of age or older? Do you have pancreatic cancer which has progressed after previous chemotherapy treatment? Are you able to make extra visits to the clinic for treatment and assessments?

Specialty Area(s)

Pancreatic Cancer

Principal Investigator

Gulam A. Manji, MD

Profile Headshot
  • Director of Gastrointestinal Oncology
  • Director of Pancreas Translational Research
  • Co-Director of The Pancreas Center

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
Open location in Google Maps